Novel Methods for Ascertainment of Gout Flares -A Pilot Study
NCT02855437 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44
Last updated 2019-10-28
Summary
The purpose of this study is to determine the feasibility and acceptability of using different remote data collection technologies to ascertain flare occurrence among gout patients. Two technologies will be the focus of this study: a telephone based interactive voice response (IVR) and a smartphone mobile application (called RheumPRO). The results of this study will not only guide research approaches in clinical trials, but may also have direct implications for monitoring patient outcomes in the context of day-to-day clinical practice.
The investigators hypothesize that acceptability will be greater for RheumPRO application than IVR. Additionally, the investigators hypothesize that RheumPRO will be associated with a greater frequency of patient-initiated interactions.
Conditions
Interventions
- DEVICE
-
IVR (Phone call)
IVR will auto dial participants at a schedule time. Participants complete questions using their phone keypad. Participants can also call the IVR to complete surveys if they experience a flare. The IVR will be programmed to call the patient weekly for 26 weeks to complete a weekly Gout Flare Survey and Patient Reported Outcomes Survey. Consistent with the published gout flare self-report definition, gout flare ascertainment questions will include whether the recent flare is similar to past flares, the number of swollen joints and the number of warm joints. Pain at rest during the attack will be assessed on a 0-9 scale. Further questions will include peak pain, timing of attack and duration of attack if completed. We will capture patient reported outcome measures (e.g. pain, fatigue, sleep) using instruments from NIH PROMIS. Following completion of 26 week IVR period participants will crossover to RheumPro arm.
- DEVICE
-
RheumPro (Smartphone application)
RheumPRO will be programmed to notify participants weekly for 26 weeks via a scheduled "pop-up" to complete Gout Flare and Patient Reported Outcomes Surveys. Participants self-navigate through the survey questions using their smartphone. If participants do not complete the Gout Flare or Patient Reported Outcomes surveys RheumPro will generate 2 more "pop-ups" at the same time over the proceeding 2 days (eg. Tuesday 4 PM, Wednesday 4 PM). Participants can also open the RheumPro application on their smartphone and complete surveys or if they experience a flare on a day they are not scheduled to complete a survey. Following completion of 26 week RheumPro period participants will crossover to IVR arm.
Sponsors & Collaborators
-
University of Nebraska
collaborator OTHER -
University of Alabama at Birmingham
lead OTHER
Principal Investigators
-
Kenneth Saag, M.D. · University of Alabama at Birmingham
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2016-09-30
- Primary Completion
- 2018-08-31
- Completion
- 2018-08-31
Countries
- United States
Study Locations
More Related Trials
-
Nurse-Led Telehealth for Gout
NCT06971146 ·Status: RECRUITING ·Phase: NA
-
Gout in the ED and Improving Research Participation
NCT04075903 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol
NCT01451645 ·Status: COMPLETED ·Phase: PHASE4
-
The Remote Monitoring of Gout Feasibility Study
NCT06211322 ·Status: COMPLETED ·Phase: NA
-
Gout Self-Monitoring Aiming to Reach Target
NCT03274063 ·Status: COMPLETED ·Phase: NA
-
Arthritis Research UK Gout Treatment Trial - Phase 2
NCT01477346 ·Status: COMPLETED ·Phase: NA
-
An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.
NCT01112982 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
NCT02063997 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
NCT06846515 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Assessing the Role of the NLRP3 Inflammasome in Intercritical Gout
NCT04125459 ·Status: ACTIVE_NOT_RECRUITING
-
Low-dose Colchicine With or Without Stepwise Dose Titration of Febuxostat for Flare Prophylaxis in Gout
NCT04697602 ·Status: TERMINATED ·Phase: NA
-
Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout
NCT01078389 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
NCT02139046 ·Status: COMPLETED ·Phase: PHASE3
-
The Remote Monitoring of Gout Study
NCT06822933 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Imagery as Biomarker of Gout
NCT05434858 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout
NCT02287818 ·Status: COMPLETED ·Phase: PHASE2
-
Relation Between Blood Concentration of Colchicine and Response to Colchicine Treatment in Gout Flare
NCT03933007 ·Status: TERMINATED ·Phase: PHASE4
-
MPC-004 for the Treatment of an Acute Gout Flare
NCT00506883 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Topical Ketorolac Gel in Acute Gouty Flare
NCT06273813 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
NCT07145229 ·Status: RECRUITING ·Phase: PHASE2
-
A Proof-of-Concept Study of AC-201 to Prevent Gout Flares
NCT01712204 ·Status: COMPLETED ·Phase: PHASE2
-
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.
NCT01080131 ·Status: COMPLETED ·Phase: PHASE3
-
Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients
NCT05586958 ·Status: COMPLETED ·Phase: PHASE3
-
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
NCT05586971 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients
NCT05119686 ·Status: COMPLETED ·Phase: PHASE2